4//SEC Filing
Powell David Jonathan 4
Accession 0000921895-20-003153
CIK 0001599298other
Filed
Nov 30, 7:00 PM ET
Accepted
Dec 1, 7:45 PM ET
Size
19.0 KB
Accession
0000921895-20-003153
Insider Transaction Report
Form 4
Powell David Jonathan
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2020-11-27$1.92/sh+16,616$31,903→ 16,616 total - Sale
Common Stock
2020-11-27$4.39/sh−29,569$129,808→ 0 total - Sale
Common Stock
2020-11-30$4.44/sh−13,713$60,886→ 0 total - Exercise of In-Money
Stock Option (right to buy)
2020-11-27$1.79/sh−12,953$23,186→ 404,686 totalExercise: $1.79Exp: 2029-03-29→ Common Stock (12,953 underlying) - Exercise/Conversion
Common Stock
2020-11-30$1.79/sh+13,713$24,546→ 13,713 total - Exercise/Conversion
Common Stock
2020-11-27$1.79/sh+12,953$23,186→ 29,569 total - Exercise of In-Money
Stock Option (right to buy)
2020-11-30$1.79/sh−13,713$24,546→ 390,973 totalExercise: $1.79Exp: 2029-03-29→ Common Stock (13,713 underlying) - Exercise of In-Money
Stock Option (right to buy)
2020-11-27$1.92/sh−16,616$31,903→ 417,639 totalExercise: $1.92Exp: 2028-10-19→ Common Stock (16,616 underlying)
Footnotes (5)
- [F1]Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices.
- [F2]The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.30 to $4.66. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
- [F3]The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.40 to $4.50. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
- [F4]The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date.
- [F5]The option was granted on March 29, 2019. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date.
Documents
Issuer
Summit Therapeutics Inc.
CIK 0001599298
Entity typeother
Related Parties
1- filerCIK 0001824493
Filing Metadata
- Form type
- 4
- Filed
- Nov 30, 7:00 PM ET
- Accepted
- Dec 1, 7:45 PM ET
- Size
- 19.0 KB